Clinical Trial Update: Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update for a single-dose live attenuated Japanese Encephalitis chimeric vaccine (IMOJEV) in healthy subjects; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IMOJEV

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2016-11-29